THE WHAT? Bridgepoint fund, Bridgepoint Europe VII has announced that it has made a strategic investment in RoC Skincare. Under the terms of the deal RoC’s existing backer, Gryphon Investors, will sell its majority stake to Bridgepoint for an undisclosed sum.

THE DETAILS The acquisition is the fund’s sixth builds on Bridgepoint’s growing track record of supporting businesses in the wider dermatology ecosystem, including Vivacy and HTL.

THE WHY? Fernando Acosta, CEO of RoC Skincare, said: “With Bridgepoint’s deep expertise in the dermatology sector and its strong European presence, RoC is poised to capitalise on the promising growth opportunities that lie ahead. I would like to thank the RoC team and Gryphon for their support over the past few years. Through the hard work and innovation of RoC’s talented team, we’ve become one of the largest independent skincare brands globally, while upholding our commitment to delivering the best clinically proven skin health solutions.”